Table 1: Otsuka - PharmaVitae forecasts at a glance 7
Table 2: Otsuka key product developments, 2008 19
Table 3: Otsuka product deals and alliances, 2008 20
Table 4: Otsuka technology deals and alliances, 2008 21
Table 5: Otsuka M&A activity, 2008 22
Table 6: Otsuka company announcements, 2008 23
Table 7: Otsuka future product milestones, 2009-11 23
Table 8: Otsuka product portfolio overview ($m), 2001-07 33
Table 9: Otsuka product portfolio overview ($m), 2007-13 36
Table 10: Otsuka product portfolio overview ($m), 2001-07 40
Table 11: Otsuka product portfolio overview ($m), 2007-13 42
Table 12: Otsuka portfolio overview by geographic region ($m), 2001-07 47
Table 13: Otsuka portfolio overview by geographic region ($m), 2007-13 49
Table 14: Otsuka launch portfolio overview ($m), 2007-13 54
Table 15: Otsuka core portfolio overview ($m), 2007-13 57
Table 16: Otsuka expiry portfolio overview ($m), 2007-13 59
Table 17: Otsuka portfolio overview by molecule type ($m), 2001-07 62
Table 18: Otsuka product portfolio overview by molecule type ($m), 2007-13 62
Table 19: Otsuka product portfolio overview by source ($m), 2001-07 66
Table 20: Otsuka product portfolio overview by source ($m), 2007-13 68
Table 21: Total Otsuka sales by business unit ($m), 2001-07 72
Table 22: Otsuka profit and loss account ($m), 2001-07 74
Table 23: Otsuka operating revenue/cost analysis ($m), 2001-07 76
Table 24: Otsuka operating cost ratio analysis (% of total revenues), 2001-07 77
Table 25: Key products overview 79
Table 26: Abilify: overview 80
Table 27: Abilify: sales forecast ($m), 2007-13 81
Table 28: Pletaal: overview 84
Table 29: Pletaal: sales forecast ($m), 2007-13 85
Table 30: TS-1: overview 86
Table 31: TS-1: sales forecast ($m), 2007-13 87
Table 32: UFT: overview 88
Table 33: UFT: sales forecast ($m), 2007-13 89
Table 34: Mucosta: overview 90
Table 35: Mucosta: sales forecast ($m), 2007-13 91
Table 36: Tetomilast: overview 92
Table 37: Tetomilast: sales forecast ($m), 2007-13 93
Table 38: Otsuka's R&D pipeline (Phase I-registration) 95
Table 39: Exchange rates, 2007 98
Figure 1: Otsuka prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: Otsuka's financial performance ($m), 2004-07 6
Figure 3: Contribution of Abilify to Otsuka's total Rx revenue performance ($m), 2001-13 8
Figure 4: Scenario analysis: impact of Abilify generics to Otsuka total Rx revenue ($m), 2001-13 9
Figure 5: Otsuka SWOT analysis 12
Figure 6: Current corporate structure 28
Figure 7: Otsuka prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 31
Figure 8: Otsuka key sales growth drivers and resistors ($m), 2001-07 34
Figure 9: Otsuka key sales growth drivers and resistors ($m), 2007-13 37
Figure 10: Otsuka prescription pharmaceutical sales by therapy area ($m), 2001-13 39
Figure 11: Otsuka prescription pharma sales by therapy area (% of total), 2001-13 44
Figure 12: Otsuka prescription pharmaceutical sales by geographic region ($m), 2001-13 46
Figure 13: Otsuka growth drivers and resistors by geographic region ($m), 2001-07 47
Figure 14: Otsuka drivers and resistors by geographic region ($m), 2007-13 49
Figure 15: Otsuka prescription pharmaceutical sales by geographic region (% of total), 2001-13 51
Figure 16: Otsuka launch/core/expiry configuration ($m), 2007-13 60
Figure 17: Otsuka prescription pharmaceutical sales by molecule type ($m), 2001-13 61
Figure 18: Otsuka growth drivers and resistors by molecule type ($m), 2007-13 63
Figure 19: Otsuka prescription pharmaceutical sales by source ($m), 2001-13 65
Figure 20: Otsuka growth drivers and resistors by source ($m), 2001-07 67
Figure 21: Otsuka growth drivers and resistors by source ($m), 2007-13 69
Figure 22: Otsuka operating revenue/cost analysis ($m), 2004-07 75
Figure 23: Otsuka operating cost ratio analysis (% of total revenues), 2004-07 77
[Tabellenverzeichnis ausblenden]
